<div id="readability-page-1"><div><p>Charles River Laboratories International (CRL) has announced a major leadership transition, with long-time CEO James C. Foster scheduled to retire in May 2026 and Chief Operating Officer Birgit Girshick named as his successor.</p> <p>See our latest analysis for Charles River Laboratories International.</p> <p>The CEO succession news comes after a strong period for the shares, with a 30 day share price return of 13.36% and a 90 day share price return of 28.62%. The 1 year total shareholder return of 15.08% compares with weaker 3 and 5 year total shareholder returns, which indicates that recent momentum has increased following leadership and M&amp;A announcements.</p> <p>If you are looking beyond Charles River Laboratories International, this could be a good moment to scan other healthcare stocks that might fit your watchlist next.</p> <p>With the shares up strongly over the past 3 months, trading at $218.82 and sitting above an average analyst price target of $203.33, the key question now is whether CRL still trades at a discount or if the market is already pricing in future growth.</p> <h2>Most Popular Narrative: 15.8% Overvalued</h2> <p>The most followed narrative sees Charles River Laboratories International trading above its fair value estimate of $188.93 compared with the last close at $218.82, and ties that gap to a detailed earnings recovery story.</p> <blockquote> <p><em>Strategic focus on cost reduction (over $175M in annualized savings expected in 2025), disciplined capital allocation, and improved working capital management not only buttress current profitability but free up cash flow for continued investment in high-growth areas and M&amp;A, strengthening long-term earnings and free cash flow generation.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Want to see what kind of revenue path, margin rebuild, and future P/E multiple are being baked into that fair value line? The narrative leans on a specific mix of modest top line growth, a sharp swing into profitability and a valuation multiple that sits below many peers yet still assumes a meaningful rerating from today. The details behind those assumptions are where the real story sits.</p> <p><strong>Result: Fair Value of $188.93 (OVERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, there is still a real risk that faster adoption of non animal methods, or sustained pressure on Discovery and Safety Assessment demand, could derail that earnings rebuild story.</p> <p>Find out about the key risks to this Charles River Laboratories International narrative.</p> <h2>Another View: Multiples Point to Value Support</h2> <p>While the popular narrative frames Charles River Laboratories International as about 15.8% overvalued versus an intrinsic value of $188.93, the market’s own pricing tells a different story. On a P/S of 2.7x, CRL trades below the US Life Sciences industry average of 3.8x and well under a 7.7x peer average, with only a small gap to a fair ratio of 2.9x that our model suggests the market could move toward. That mix of discount to peers and only a modest premium to fair ratio raises a simple question for you: is the crowd too cautious about execution and growth, or are the narrative risks still underappreciated?</p> <p>See what the numbers say about this price — find out in our valuation breakdown.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4fd3e71b-c9b2-4cab-885d-16673cf937e8/chart/ps-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4fd3e71b-c9b2-4cab-885d-16673cf937e8/chart/ps-multiple-vs-industry"/><figcaption>NYSE:CRL P/S Ratio as at Jan 2026</figcaption></figure><h2> Build Your Own Charles River Laboratories International Narrative</h2> <p>If you see the numbers differently, or simply prefer to test your own assumptions against the data, you can build a complete view in minutes: Do it your way.</p> <p>A great starting point for your Charles River Laboratories International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.</p> <h2>Looking for more investment ideas?</h2> <p>If you stop with just one company, you could miss opportunities that fit your style much better, so take a few minutes to scan a wider set of ideas.</p> <ul> <li>Target potential mispricings by checking out these 878 undervalued stocks based on cash flows that might offer a more attractive entry based on their cash flow profiles.</li> <li>Ride powerful tech trends by reviewing these 26 AI penny stocks where artificial intelligence is a core part of the business model.</li> <li>Boost your income focus by scanning these 12 dividend stocks with yields &gt; 3% that may suit a portfolio built around regular cash returns.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

<p>Charles River Laboratories (CRL) is undergoing a leadership transition with CEO James C. Foster retiring in May 2026, succeeded by COO Birgit Girshick. The company has seen a strong share price performance, with a 30-day return of 13.36% and a 90-day return of 28.62%. However, it is considered overvalued at $218.82 compared to a fair value of $188.93. Analysts highlight risks related to non-animal methods and demand pressures, while also noting CRL's lower price-to-sales ratio compared to industry peers, suggesting potential market caution.</p>

A Look At Charles River Laboratories (CRL) Valuation As CEO Succession Plan Takes Shape